Evgen Pharma Share Discussion Threads

[moneymunch] 01/6/2021 08:44

Multiple material newsflow, stacking UP!!! Gla :-)

[bumpa33] 01/6/2021 08:17

Then again, we’re all expecting news!

[bumpa33] 01/6/2021 08:16

Friday’s late flurry looked like some might have been expecting news.

[moneymunch] 31/5/2021 19:10

A very strong indication on why Jim Mellon and maybe Octopus bought in. Gla :-)


NEWS RELEASE 2-FEB-2021

Aging-US: Sulforaphane promotes C. elegans longevity and healthspan

"The results in this Aging-US research output, indicate that sulforaphane prolongs the lifespan and healthspan of C. elegans through insulin/IGF-1 signaling."

...............

Here, the authors asked whether sulforaphane may influence the lifespan and healthspan of C. elegans.

They found that sulforaphane significantly extends the lifespan of C. elegans and delays age-related phenotype changes.

The analysis of wild-type C. elegans and 9 mutant strains revealed that sulforaphane inhibited DAF-2 insulin/insulin receptor signaling and thereby increased DAF-16 nuclear translocation, resulting in the expression of the sod-3, mtl-1 and gst-4 target genes, which are known mediators of longevity in C. elegans.

The Herr Research Team concluded in their Aging-US Research Paper, "we are the first to report that sulforaphane prolongs the lifespan and increases the healthspan of C. elegans through the inhibition of DAF- 2/insulin/IGF-1 signaling and the activation of DAF- 16/FOXO nuclear transcription in C. elegans. Our study provides a promising hint regarding the suitability of sulforaphane as a new anti-aging drug. However, additional studies in invertebrates and mammalian model organisms are necessary to expand our findings."

[moneymunch] 31/5/2021 19:07

Boom time - Jim Mellon Interview

Longevity science will, I think, lead to the biggest stock market boom ever. It will make the recent medical cannabis boom look like nothing. For the first time in the history of mankind, the elixir of youth, the promise of living a longer life, will actually come true.

There is no one pill that you can take, but a combination of several pharmaceuticals, gene therapies, gene-related technology and treatments could extend your lifespan to 120.

I’m confident in predicting that the science of longevity will represent the biggest industry on the planet within 20 years, and that it will be affordable for everyone after about ten years of commercial exploitation.

Wear and tear

It is important to note that we’re not predestined to die. But as time goes on, the healing process of our body gets overwhelmed – wear and tear overwhelms repair.

We gradually go into a process called ‘loss of homeostasis’, which signals that our inner chemical balance is beginning to get upset, which eventually results in death.

There are some creatures out there, such as the C. elegans worm, which Google’s ageing company Calico is studying, that are made up of atoms and molecules just like us but don’t die naturally. Science has shown that the lifespan of a worm can be increased by up to 20 times using genetic manipulation.

Similar principles can apply to humans. There is a huge amount of bioscience activity in the UK, which is not widely known. There have been negative developments in the form of Neil Woodford’s investments and the government’s lack of funding in this area.

But now people like Sir John Bell are spearheading major efforts to build a home-grown industry. Increasingly, the nexus between VC universities and scientist-entrepreneurs that’s made the US so successful in this field is developing in the UK.

More Juvenescence employees are based here than anywhere else, so we’re very much British. It’s very important to us that the UK retains its status as the second major centre for life sciences in the world.

[moneymunch] 31/5/2021 18:37

Octopus know when they're on to a winner...Gla :-)



With more than £1 billion under management today, Octopus Ventures started out as a generalist Venture Capital (VC) firm, but in recent years has focused on three key pillars of investment: Deep Tech, Future of Money and Future of Health.

Uzma is focused on assessing investment opportunities, conducting preliminary due diligence and executing deals. Her experience straddles the Deep Tech and Future of Health Pods, and she is now focused on Frontier Technologies within health and biotech such as synthetic biology and nanotech, genomics, gene editing and computational biology. This includes platforms at the intersection of technology and biology, including human augmentation and neurotech.

“We’re starting to build more expertise in the frontier technologies within health and seeing a number of life sciences opportunities which fit in that bracket,” she says. “And that’s where we feel there’s an overlap between deep tech and health.”

“… we asked ourselves whether Longevity is a space we should be looking at? … We think it is because the areas that we want to look at are those where we think there is a large opportunity or big global challenges that we could be solving. Longevity certainly ticks that box …”

 

In terms of biohacking specifically, Choudry, with a PhD in synthetic biology and biophysics, has a keen personal interest. She points at the opportunity presented by advancements in the genomics space – initially around the ability to read the “biological” software (genome) through more cost-effective DNA sequencing technology, but further now in developments around gene editing tools, such as CRISPR-Cas3/9, which provide the ability to write and edit the software/genes, and opening up a massive opportunity.

........

As far as her views on Longevity as a sector goes, Choudry has spent time with Juvenescence’s Jim Mellon and the people who manage his investment funds.

“There were interesting views on lifespan versus health span, and we asked ourselves whether Longevity is a space we should be looking at?” she says. “We think it is because the areas that we want to look at are those where we think there is a large opportunity or big global challenges that we could be solving. Longevity certainly ticks that box, the aging population is something that is at the front of our mind. Probably more so around health span rather than lifespan – how are these people able to keep good health into their later years. Those are some of the areas that we are looking at within our future of health team.”

[bocker01] 31/5/2021 18:04

I should be! Hope you are good and all is well!

[mesquida] 31/5/2021 17:31

Bocker, what a quick response ! Why aren't you on the beach ?!

[bocker01] 31/5/2021 17:29

Yes very much so Mesquida. A trifle short of the market cap on their own based on a follow through royalties stream sufficient to apply a half decent pe.

[mesquida] 31/5/2021 17:23

Yes, bocker, the immediate cash benefits of the Mellon deal have certainly been ignored, the milestone payments, amounting to approx.$10m over the next 2 years, are very relevant in the context of our current market cap of only £23m ( of which half is already cash ). Granted there will be cash burn for a few years, but surely at this level Evogen is priced for failure, and only for failure.

[bocker01] 31/5/2021 17:02

The Mellon deal seems largely ignored whilst increased longevity is the biggest potential market ever. Still even so it has immediate cash benefits also ignored. Maybe a shareholder SFX product very deep discount will be advised.

[moneymunch] 31/5/2021 14:20

Great find On Target....Gl :-)

[bumpa33] 31/5/2021 12:38

thanks for posting that video OT. Clearly longevity therapeutics/nutraceuticals will be a massive market opportunity in the years to come - anti-aging/disease prevention and the prolonging of quality life being the ultimate holy grail. Some really interesting stuff in that interview - maybe as said, the ‘science fiction’ is becoming science.

[dlg3] 30/5/2021 21:28

Evgen Pharma’s core technology is Sulforadex®, a means of synthesising and concurrently stabilising the naturally occurring compound sulforaphane (or novel analogues based upon sulforaphane). Pure sulforaphane is an unstable oily liquid, which needs to be stored at -20 degrees C. A significant and growing amount of academic research has focused on sulforaphane but this work has been conducted either with frozen botanical extracts containing unstable sulforaphane or ambient temperature botanical extracts containing glucoraphanin, the chemical precursor of sulforaphane.

[dlg3] 30/5/2021 20:37

Sulforaphane, a compound found in broccoli sprouts, has been shown to benefit autism in a way no drug ever has in a randomized, double-blind, placebo-controlled study.

Secret broccoli ingredient may hold key to preeclampsia treatment

Sulforaphane May Prevent Alzheimer’s

Broccoli could be key in the fight against osteoarthritis

Sulforaphane has been researched for 25 years for its apparent preventive properties against cardiovascular disease, type 2 diabetes and cancer.

In a series of recently published studies using animals and people, researchers say they have further characterized a set of chemical imbalances in the brains of people with schizophrenia related to the chemical glutamate. And they figured out how to tweak the level using a compound derived from broccoli sprouts.

Sahlgrenska Academy, University of Gothenburg, and the Faculty of Medicine at Lund University in Sweden found that extracts of broccoli can be quite effective in managing the symptoms of Type 2 diabetes.

Sulforaphane kills human leukemia cells in the lab, and studies have shown that high daily dietary cruciferous intake decreases the risk of lymphoma.

Broccoli May Slow or Reverse Some Atherosclerosis

The research also describes the potential of clinical candidate SFX-01 (a novel formulation of sulforaphane) for improving clinical outcomes in ER-positive breast cancer.

Broccoli Extract May Prevent Throat And Neck Cancer Recurrences

[dlg3] 30/5/2021 20:22

Metabolic Switch

$24.95
$12.47/serving

How often should I take Metabolic Switch?

We recommend that you drink an entire bottle of Metabolic Switch daily. Scientists believe that any time your body is burning ketones, rather than sugar, for energy, you’re supporting a healthy metabolism and fueling your cells. That said, if you miss a serving or aren’t able to incorporate a daily regimen, you can still reap the benefits of Metabolic Switch if you take it as often as you’re able to.

$12.95 X 365 $4716.75 YEARLY ONE PERSON

hxxps://www.juvlabs.com/shop/metabolic-switch

Shows the potential with sulforaphane

[dlg3] 30/5/2021 20:11

Market for vitamins and supplements will turn over US $ 252 billion in 2025

hxxps://g1.globo.com/bemestar/blog/longevidade-modo-de-usar/post/2021/05/20/mercado-de-vitaminas-e-suplementos-movimentara-252-bilhoes-de-dolares-em-2025.ghtml

[holycow1] 30/5/2021 19:32

just one of many of its applications.

With the Chief Business Officer now in place.
With the scale up of production.
With the tablet form now at the pharmaceutical level.

Are we expecting a barrage of RNSs from different Pharmas licencing SFX-01
for different applications?

With sulforaphane showing so much promise, with so many trials being carried out using sulforaphane surely the big pharmas need to help Evgen out with the many many trials?...ie licence SFX-01?

[muddy_40] 30/5/2021 13:59

I think Sulforaphane was to be launched in next 2 years. I thought it interesting his body language when he introduced Sulforaphane.

Just one of many of its applications.

[on target] 30/5/2021 13:54

One of four supplement products is how I heard it, the others being ketone esters (already launched as Metabolic Switch), spermidine and plasmologens. Aiming to release one product every year over 4 years.

[peanut100] 30/5/2021 12:39

Even 5% would be huge if successful with the numbers he speaks of. Great find thank you

[pdt] 30/5/2021 12:00

On Target - thanks for sharing, interesting to listen to that video.

[on target] 30/5/2021 11:28

Interview with Gregory Bailey CEO of Juvenescence 29/5/21



8:50-10:10 talks about their (Evgen's) Sulforaphane supplement

17:00 onwards talks about pricing/volume strategy - big bucks.

Wonder what the royalties are, because this could be a big earner for EVG.